Optofluidic chip platform developed for single molecule analysis
A new platform has enabled an unprecedented level of control over individual molecules and particles on a chip for high-throughput analysis.
List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
A new platform has enabled an unprecedented level of control over individual molecules and particles on a chip for high-throughput analysis.
The advantages of detection of oxidative stress by high content analysis.
Cell death is a process that occurs as both a part of normal tissue homeostasis and can be aberrantly regulated in some disease states, specifically cancer.
Researchers may have fundamentally altered the way scientists study brain diseases with new CRISPR technology.
A new experiment has not only slowed the progression of the prion disease, scrapie, it also extended the lives of prion-infected mice
Molecular Devices, LLC, today announced the launch of the next generation of its FLIPR® Penta High-Throughput Cellular Screening System.
Prediction of Aggregation Propensity and Monitoring of Aggregation of Antibody-Drug Conjugates (ADC).
A review has been published by experts in neurodegeneration research, detailing six ways to improve dementia research. This article investigates one of these suggestions, focusing on how we can improve drug target identification.
Researchers used screening to discover genes that protect the body against the Zika virus, which could inform potential therapies against the virus.
Researchers have developed a chip which facilitates and accelerates active substance production, characterisation and biological effectiveness.
This advanced flow cytometry platform is a complete instrument, reagents and software solution streamlined to rapidly generate results not just data.
Unique considerations surrounding the bureaucracy and oversight in the use of human biospecimens in the European Union.
High content data derived for complex immuno-oncology research facilitates a deeper understanding of the tissue microenvironment.
A recent study has identified the DBC1 gene which leaves cancer cells more exposed to therapies.